Vivek Subbiah: When JAMA publishes a phase 1 study, it will be a practice-changing study in the future- Lepodisiran

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:

“When JAMA publishes a phase 1 study, it will be a practice-changing study in the future- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations.”

For details click here.
Source: Vivek Subbiah/LinkedIn